NeoTract’s UroLift System won the 2016 “Most Promising New Product” award at the 23rd Phoenix Medical Device CEO Conference Oct. 5-7 in Laguna Beach, California.
The UroLift System was recognized for its innovative, minimally invasive approach for relieving symptoms caused by benign prostatic hyperplasia (BPH).
“It is very gratifying to be recognized by the Phoenix Conference organizers and conference attendees, leaders who have developed many breakthroughs that have revolutionized the treatment of a wide variety of conditions,” Dave Amerson, president and CEO of NeoTract, said in a press release.
“UroLift’s selection as the most promising new product from an impressive field of innovations is exciting. We are pleased that our peers recognize the system’s benefits for physicians and for the millions of men who suffer from BPH,” he added.
The 23rd Phoenix conference gathered top-level executives from large healthcare companies and CEOs of small venture-backed firms to discuss issues of interest to the medical device industry today. The Phoenix Awards recognize outstanding products in the medical device and diagnostic industry.
UroLift is a U.S. Food and Drug Administration (FDA)-cleared and minimally invasive approach to treating lower urinary tract symptoms due to an enlarged prostate, or BPH. There is no cutting, heating, or removal of prostate tissue. UroLift’s permanent implants, delivered through an outpatient transurethral procedure, are designed to relieve prostate obstruction and open the urethra.
“The original vision for the UroLift device was to develop an innovative solution for BPH that involved no cutting, heating or removal of tissue, in a simple and intuitive procedure,” said Ted Lamson, PhD, founder and CEO of NeoTract.
“Bringing the device from concept to fruition has been incredibly rewarding, and is the result of the commitment and dedication of the NeoTract team and many collaborative physicians who share our vision for new, better solutions for BPH,” he said.
In August, NeoTract published four-year follow-up results from its pivotal L.I.F.T. IDE trial in the journal Urologic Clinics of North America, titled “Prostatic Urethral Lift: A Unique Minimally Invasive Surgical Treatment of Male Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.”
L.I.F.T (NCT01294150), was a multi-center, randomized, patient- and outcome assessor-blinded trial that evaluated the safety and effectiveness of the Prostatic Urethral Lift (PUL) in men with lower urinary tract symptoms (LUTS). Results showed that over 86 percent of the original group of patients enrolled after four years no longer sought additional treatment for BPH.
A second clinical trial, BPH6 (NCT01533038), compared the UroLift System to transurethral resection of the prostate (TURP) in improving a patient’s overall quality of life, while evaluating healthcare expenditures associated with each therapy. The results showed the UroLift device compares well to TURP regarding effectiveness, and is superior to TURP at preserving sexual function and offering a more rapid recovery.